At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Ticagrelor +1 moredrug
Likely dose
Ticagrelor 90mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
In Brief
A Phase 4 clinical trial evaluating Ticagrelor and Clopidogrel for Stable Coronary Artery Disease. Completed, enrolled 50 participants across 8 sites.
Detailed Summary
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Coronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartMar 2012
Primary CompletionSep 2013
TodayJul 2026
First PostedFeb 1, 2012
Enrollment StartMar 1, 2012
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.4 years ago
Interventions
Ticagrelordrug
Min - 90mg/Max - 180mg tablets (loading dose)
Clopidogreldrug
75mg (once daily)/Max - 600mg tablets (loading dose)